Launched in 2005, TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new molecules - chemical and biological - in diverse therapeutic areas, such as infection, neuroscience, and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics in early phases of R&D, with a view to then enter into collaboration deals for pre-clinical and/or clinical development.
TechnoPhage is developing proprietary drug discovery products from discovery to clinical stage. The company successfully developed one of its products into clinical Phase I. TechnoPhage is focused on increasing its portfolio of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across Europe, USA, and Asia.
Company is located in Lisbon in close proximity to the renowned Santa Maria Hospital and the iMM – Instituto de Medicina Molecular, which help facilitate the creation of multidisciplinary teams essential to the process of translational medicine. Furthermore, this proximity helps to facilitate access to the necessary equipment and talent required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.
TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.
TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development and GMP production.
Our track record
TechnoPhage has key partnerships with leading players in both National and International pharmaceutical industry. Under partnering agreements, TechnoPhage has taken several products into pre-clinical testing and one to clinical trials.
Technophage launched in 2019 Vision AB a spin-off company dedicated to developing small domain antibody (SdAb) targeting ophthalmology indications.
VectorB2B (www.vectorb2b.com) is a private association formed in January 2019 between Portuguese private and public partners, including Technophage. The aim is to gather the scattered capacities of the academic and industrial shareholders in the sector of health biotechnology and transform these into viable economical assets, by providing integrated services in drug discovery and screening, project design and implementation, contract research and contract manufacturing.
Since the 1st January 2020, Technophage is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.